NT-proBNP Levels During Triple Therapy With Formoterol/Glycopyrrolate/Budesonide in Patients With COPD. - Trial NCT06317428
Access comprehensive clinical trial information for NCT06317428 through Pure Global AI's free database. This phase not specified trial is sponsored by Istituto Nazionale di Ricovero e Cura per Anziani and is currently Recruiting. The study focuses on COPD. Target enrollment is 29 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Istituto Nazionale di Ricovero e Cura per Anziani
Timeline & Enrollment
N/A
Jun 28, 2022
Dec 31, 2025
Primary Outcome
Change in serum NT-pro-BNP levels
Summary
Observational prospective study to evaluate serum NT-proBNP levels in a population of COPD
 patients three months after the iniation of triple inhaled
 formoterol/glycopyrrolate/budesonide therapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06317428
Non-Device Trial